NUV-1511
- Generic Name
- NUV-1511
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Pancreatic CancerMetastatic Castration-resistant Prostate Cancer (mCRPC)Advanced Solid TumorPlatinum-resistant Ovarian Cancer (PROC)HER2-negative Breast Cancer
- Interventions
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Nuvation Bio Inc.
- Target Recruit Count
- 466
- Registration Number
- NCT06334432
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Fred Hutchinson, Seattle, Washington, United States
🇺🇸Karmanos Cancer Center, Detroit, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath